Business Context and Reporting Period
This Form 8-K Current Report was filed by Rocky Mountain Chocolate Factory, Inc. (RMCF) on September 15, 2025. The filing addresses a material change in corporate governance involving the resignation of a director and the subsequent receipt of a non-compliance notice from The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide specific financial data regarding revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and listing status.
Material Changes
- Director Resignation: Allen C. Harper resigned from the Board of Directors and all committees effective immediately on September 15, 2025. The resignation was attributed to other professional responsibilities and not due to any disagreement with the Company.
- Nasdaq Non-Compliance: On September 17, 2025, the Company received a notice from Nasdaq stating it is no longer in compliance with Listing Rule 5605 (Corporate Governance Requirements) due to the resignation. Specifically, the Board no longer has a majority of Independent Directors, and the Audit Committee no longer meets the requirement of having at least three independent members.
Outlook, Management Commentary, and Risks
- Cure Period: The Company is entitled to a cure period to regain compliance, expiring on the earlier of its next annual meeting of stockholders or September 15, 2026.
- Management Plan: The Company intends to appoint an additional independent director to the Board and the Audit Committee prior to the end of the cure period.
- Trading Status: The non-compliance notice has no immediate effect on the listing or trading of RMCF common stock on The Nasdaq Capital Market.
- Risk Factors: The filing includes a standard cautionary note regarding forward-looking statements, citing risks such as inflation, legal proceedings, raw material costs, competition, and regulatory changes.
Investor Verification Checklist
- Verify the current composition of the Board of Directors to confirm the number of independent directors.
- Monitor future filings for the appointment of a new independent director to satisfy Nasdaq Rule 5605.
- Review the Company's most recent Form 10-Q (ended May 31, 2025) and Form 10-K (ended February 28, 2025) for detailed financial performance and risk factors not included in this 8-K.
- Confirm the date of the next annual meeting of stockholders to determine the exact expiration of the cure period.